Clinical Trials Sponsored by Advanz Pharma

Total 8486 results

Advanz Pharma

Completed

Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study

Atrial Fibrillation

Spain, Netherlands, New Zealand, Australia, Sweden, Denmark, Slovakia, Belgium, Estonia, Serbia, Russian Federation, Czech Republic, Bulgaria, Germany, Portugal, Croatia, Switzerland, Hungary, Lithuania, Poland, Romania, Singapore, South... and more
Advanz Pharma

Completed

A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)

Atrial Fibrillation
Advanz Pharma

Withdrawn

A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)

Atrial Fibrillation
Advanz Pharma

Completed

Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence

Atrial Fibrillation

Netherlands, United States, Canada, Denmark
Advanz Pharma

Completed

Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure

Congestive Heart Failure

United States
Advanz Pharma

Terminated

A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045) (ACT V)

Atrial Fibrillation
Advanz Pharma

Completed

A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation (AVRO)

Atrial Fibrillation

Australia, Netherlands, Canada, France, Germany, Lithuania, Ukraine, Czech Republic, Denmark, Estonia, Finland, Latvia, Poland, Serbia, Slovakia, Sweden
Astellas Pharma Inc
Advanz Pharma

Completed

Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter

Atrial Fibrillation | Atrial Flutter

United States, Argentina, Canada, Chile, Denmark, Mexico, Sweden
Astellas Pharma Inc
Advanz Pharma

Completed

Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation (ACT 4)

Atrial Fibrillation

United States, South Africa, Canada, Argentina, Denmark, Sweden
Advanz Pharma
Astellas Pharma US, Inc.

Completed

A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter (Scene 2)

Atrial Flutter

United States, Canada, Denmark, Sweden
Advanz Pharma
Astellas Pharma US, Inc.

Completed

Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation (ACT I)

Atrial Fibrillation

United States, Canada, Sweden, Denmark
Correvio International Sarl

Completed

Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)

Atrial Fibrillation

Denmark, Spain, Austria, Finland, Germany, Sweden
Astellas Pharma Inc
Astellas Pharma US, Inc.; Advanz Pharma

Completed

Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery

Atrial Fibrillation | Atrial Flutter

Poland, United States, Canada, Argentina, Denmark, India
Uppsala University Hospital
Swedish Heart Lung Foundation; Advanz Pharma

Completed

Electrical Cardioversion of Recent Onset Atrial Fibrillation - Silent Thromboembolic Events, Reverse Atrial Remodeling (ECAF-STAR)

Intracranial Embolism

Sweden
Correvio International Sarl
PrimeVigilance; Universal Medical Group

Completed

Xydalba Utilization Registry in France

Bacterial Infections

France
Advanz Pharma
AMS Advanced Medical Services GmbH; APCER Life Sciences

Completed

Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain Diseases (RETRACE)

Hepatic Insufficiency | Renal Insufficiency | Immunosuppression

Spain, France, Germany, Italy
Correvio International Sarl
PrimeVigilance; AMS Advanced Medical Services GmbH

Terminated

Xydalba Utilization Registry in Germany

Bacterial Infections

Germany
R-Pharm
Covance; Cromos Pharma LLC

Withdrawn

Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).

COVID-19
Organ, Tissue, Regeneration, Repair and Replacement
Euraxi Pharma; ARANZ Medical

Recruiting

CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa (MATHBULL)

Epidermolysis Bullosa Dystrophica | Epidermolysis Bullosa, Junctional

France
UCB BIOSCIENCES, Inc.
R-Pharm

Terminated

Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

Rheumatoid Arthritis

United States, Belgium, United Kingdom
AJU Pharm Co., Ltd.
OM Pharma SA

Recruiting

The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Chronic Prostatitis With Chronic Pelvic Pain Syndrome | Chronic Prostatitis | Chronic Pelvic Pain Syndrome

Korea, Republic of
UCB BIOSCIENCES, Inc.
R-Pharm

Terminated

The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Japan, Korea, Republic of, Taiwan
Yuria-Pharm
Pharmaxi LLC

Completed

Epidemiological Study of the COVID-2019 in Participating Organizations.

Covid19

Ukraine
Ranjana Advani
Genentech, Inc.

Completed

Rituximab in Treating Patients With Hodgkin's Lymphoma

Lymphoma | Hodgkin Lymphoma (Category) | Nodular Lymphocyte Predominant Hodgkin Lymphoma

United States
Advance Biofactures Corporation

Completed

Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)

Leiomyoma | Fibroids, Uterine

United States
Avant Immunotherapeutics

Completed

Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery

Myocardial Ischemia | Mitral Valve Insufficiency | Aortic Valve Insufficiency | Coronary Arteriosclerosis

United States
Assistance Publique - Hôpitaux de Paris
Advanz Pharma; Centre Hospitalier de Perigueux; CHU de Nantes; Centre National...

Recruiting

Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus (DALICATH)

Staphylococcus Aureus Infection | Catheter Bacteremia

France
Avant Immunotherapeutics

Completed

Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects

Typhoid Fever

United States
PT Sydna Farma
PT Pharma Metric Labs

Completed

Bioequivalence Study of Cyproterone Acetate and Ethinyl Estradiol in Healthy Female Volunteers

Drug Use

Indonesia
Monash University
Caring Pharmacy; Bionime Corporation; Tigas Pharma

Active, not recruiting

Prevention and Treatment of Diabetes in Adults

PreDiabetes

Malaysia
Advance Shockwave Technology GmbH

Unknown

Extracorporeal Shock Wave Lithotriptor Indicated for Fragmenting Urinary Stones in the Kidney

Kidney Stones

United States
UCB Biopharma S.P.R.L.
Pharm Research Associates (UK) Ltd.

Completed

Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures (BASE)

Epilepsy With POS With or Without Secondary Generalization

Denmark, Germany, Hungary, Ireland, Italy, Netherlands, Norway, Spain, United Kingdom
UCB Pharma SA

Completed

Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

Epilepsy

United States, Belgium, Czechia, France, Germany, Hungary, Ireland, Italy, Mexico, Poland, Spain, United Kingdom
UCB Pharma SA

Completed

Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam

Epilepsy, Partial

Canada, United States
Vifor Pharma, Inc.

Terminated

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia (EMERALD)

Hyperkalemia

United States, Bulgaria, Canada, Georgia, Germany, Poland, Ukraine
UCB Pharma SA

Completed

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Epilepsy

Belgium, Finland, France, Germany, Hungary, India, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom
UCB Pharma SA

Completed

Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy

Generalized Epilepsy
UCB Pharma SA

Completed

Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)

Dermatitis, Atopic
UCB Pharma SA

Completed

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] (PRECiSE 3)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine, Canada and more
NicOx
Theradis pharma; Iris Pharma

Withdrawn

Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240) (Goldeneye)

Adenoviral Conjunctivitis

Spain
UCB Pharma GmbH

Completed

Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy (VICTOS)

Focal Epilepsy With and Without Secondary Generalization

Germany, Austria
UCB Pharma SA

Completed

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults

Unverricht-Lundborg Disease

France, Italy, Sweden, Finland, Netherlands, Tunisia, Réunion
UCB Pharma SA

Completed

Bioavailability/Bioequivalence Study Between Lacosamide Tablet and Solution for Infusion in Healthy Japanese Subjects

Healthy Volunteers

United Kingdom
UCB Pharma SA

Terminated

Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease (REFRESH-PD)

Advanced Idiopathic Parkinson's Disease

United Kingdom
PT. Pyridam Farma Tbk
PT Pharma Metric Labs

Completed

Bioequivalence Study of Metformin Hydrochloride 500 mg Film-Coated Tablets in Indonesia Healthy Subject

Drug Use

Indonesia
Laboratories Leon Farma, S.A.
Chemo France

Completed

Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles

Contraception

United States
UCB Pharma SA

Completed

Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes

Narcolepsy With Cataplexy

Belgium
UCB Pharma SA

Completed

A Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects

Healthy Volunteers

Netherlands
UCB Pharma SA

Completed

Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)

Epilepsy

United States, France, Germany, Spain, United Kingdom
UCB Pharma GmbH

Completed

Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease (NEUPAD)

Idiopathic Parkinson's Disease

Germany, Austria

Clinical Trials Sponsored by Advanz Pharma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations